Literature DB >> 15372482

The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.

Paolo G Gobbi1, Chiara Broglia, Giuseppe Di Giulio, Monica Mantelli, Paola Anselmo, Francesco Merli, Pier L Zinzani, Gabriele Rossi, Vincenzo Callea, Emilio Iannitto, Marco Paulli, Lorena Garioni, Edoardo Ascari.   

Abstract

BACKGROUND: The authors investigated the clinical role of tumor burden (TB) in patients with Hodgkin lymphoma, relating this parameter to most of the current clinical and prognostic factors and to the best predictive multifactorial models.
METHODS: The volume of TB at diagnosis was measured directly from the initial staging computed tomography scans in 351 patients who were treated on standard protocols. The mean patient age was 34.0 years +/- 16.4 years. Forty-six patients had clinical Stage I disease, 201 patients had Stage II disease, 64 patients had Stage III disease, and 40 patients had Stage IV disease. There were 146 symptomatic patients. Overall survival (OS), disease-free survival (DFS), and time to treatment failure (TTF) were the time parameters evaluated in the multivariate analysis. Logistic regression was applied according to those who achieved or failed complete remission.
RESULTS: The mean TB normalized to body surface area (rTB) was 137.8 cm(3)/m(2) +/- 124.7 cm(3)/m(2) (range, 1.9-694.5 cm(3)/m(2)). In multivariate analysis, rTB was the best predictor of TTF, DFS, and complete remission; the second best predictor of OS after patient age; and largely superior to all prognostic models analyzed. For the same stage and treatment, patients who were destined to clinical failure had an initial rTB 60-108% higher compared with the initial rTB in patients who achieved a cure, whereas differences in drug dose intensity were not significant.
CONCLUSIONS: In the current study, it was found that the rTB, as a prognostic factor, was more effective than and was independent of hitherto used factors and scores. The rTB may be a tool for evaluating the curative potential of treatment combinations, allowing physicians and patients to make better therapeutic choices earlier.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372482     DOI: 10.1002/cncr.20568

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tumor burden analysis on computed tomography by automated liver and tumor segmentation.

Authors:  Marius George Linguraru; William J Richbourg; Jianfei Liu; Jeremy M Watt; Vivek Pamulapati; Shijun Wang; Ronald M Summers
Journal:  IEEE Trans Med Imaging       Date:  2012-08-07       Impact factor: 10.048

2.  Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Authors:  Pier Luigi Zinzani; Luigi Rigacci; Vittorio Stefoni; Alessandro Broccoli; Benedetta Puccini; Antonio Castagnoli; Luca Vaggelli; Lucia Zanoni; Lisa Argnani; Michele Baccarani; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-06       Impact factor: 9.236

3.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Authors:  Salim Kanoun; Cédric Rossi; Alina Berriolo-Riedinger; Inna Dygai-Cochet; Alexandre Cochet; Olivier Humbert; Michel Toubeau; Emmanuelle Ferrant; François Brunotte; René-Olivier Casasnovas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-09       Impact factor: 9.236

4.  Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Shin Young Jeong; Sang-Min Lee; Jun-Shik Hong; Ari Chong; Joon-Ho Moon; Ji-Hyun Kim; Seok-Mo Lee; Seong Jang Kim; Ho-Jin Shin
Journal:  Cancer Sci       Date:  2013-10-23       Impact factor: 6.716

Review 5.  Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.

Authors:  Martin Pesta; Dattatrya Shetti; Vlastimil Kulda; Tereza Knizkova; Katerina Houfkova; Mahyar Sharif Bagheri; Martin Svaton; Jiri Polivka
Journal:  Diagnostics (Basel)       Date:  2022-07-25

6.  Understanding quality and equity: patient experiences with care in older adults diagnosed with hematologic malignancies.

Authors:  Alex Fauer; Sung Won Choi; Lauren P Wallner; Matthew A Davis; Christopher R Friese
Journal:  Cancer Causes Control       Date:  2021-02-10       Impact factor: 2.506

7.  Automatic liver tumor segmentation on computed tomography for patient treatment planning and monitoring.

Authors:  Mehrdad Moghbel; Syamsiah Mashohor; Rozi Mahmud; M Iqbal Bin Saripan
Journal:  EXCLI J       Date:  2016-06-27       Impact factor: 4.068

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.